The U.S. Food and Drug Administration approved Phathom Pharmaceuticals Inc.’s Voquezna Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquezna Dual Pak (vonoprazan tablets, amoxicillin capsules) for the treatment of Helicobacter pylori infection in adults.
Some of the best medicines happen by accident, according to BioSpace. The discovery of insulin began with two doctors removing the pancreas of a healthy dog in an attempt to understand its impact on digestion. Penicillin grew out of an unrelated scientific experiment involving Staphylococcus bacteria colonies. Will someone one day write the same of Novartis’ branaplam in correlation with Huntington’s disease?
Ovid Therapeutics has partnered with AstraZeneca for exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including OV350 — the lead candidate.
Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.
Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.
The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.
BioSpace takes a look at some of the top stories from day one of the Annual Biomarkers for Alzheimer’s Disease Summit held August 25-26, 2021.
Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.
Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.
Regeneron Pharmaceuticals Inc. and AstraZeneca today announced that the companies entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.